amphetamine has been researched along with guanfacine in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrews, PR; Craik, DJ; Martin, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Korada, S; Raballo, R; Shashikant, CS; Shin, DM; Simeone, A; Taylor, JR; Vaccarino, F | 1 |
| Ginsberg, LD; Greenbaum, M; Murphy, WR; Spencer, TJ | 1 |
| Bidwell, LC; Kollins, SH; McClernon, FJ | 1 |
| McBurnett, K; Rugino, T; Turnbow, J; White, C; Wilens, TE; Youcha, S | 1 |
| Abdelghany, O; Cosgrove, KP; D'Amico, C; Gaiser, EC; Matuskey, D; McKee, SA; Perkins, E | 1 |
| Lachaine, J; Mathurin, K; Sikirica, V | 1 |
| Bai, Z; Charach, A; Chojecki, D; Eagles, C; Elliott, J; Hossain, A; Hsieh, SC; Husereau, D; Johnston, A; Kelly, SE; Mamdani, M; Skidmore, B; Tsakonas, E; Wells, GA | 1 |
3 review(s) available for amphetamine and guanfacine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Cognitive enhancers for the treatment of ADHD.
Topics: Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cholinergic Agents; Clonidine; Cognition; Executive Function; Guanfacine; Humans; Intelligence; Methylphenidate; Nootropic Agents; Propylamines; Reward; Social Behavior | 2011 |
Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
Topics: Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bayes Theorem; Bupropion; Central Nervous System Stimulants; Dextroamphetamine; Drug-Related Side Effects and Adverse Reactions; Female; Guanfacine; Humans; Lisdexamfetamine Dimesylate; Male; Methylphenidate; Modafinil; Network Meta-Analysis; Quality of Life; Randomized Controlled Trials as Topic | 2020 |
2 trial(s) available for amphetamine and guanfacine
| Article | Year |
|---|---|
Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic alpha-Agonists; Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Guanfacine; Humans; Male; Methylphenidate; Psychiatric Status Rating Scales; Severity of Illness Index | 2009 |
Morning and Evening Effects of Guanfacine Extended Release Adjunctive to Psychostimulants in Pediatric ADHD.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Amphetamine; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Guanfacine; Humans; Male; Methylphenidate; Parents; Schools; Treatment Outcome | 2017 |
5 other study(ies) available for amphetamine and guanfacine
| Article | Year |
|---|---|
Functional group contributions to drug-receptor interactions.
Topics: Animals; Calorimetry; Kinetics; Models, Biological; Protein Binding; Receptors, Cell Surface; Receptors, Drug; Structure-Activity Relationship | 1984 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Loss of glutamatergic pyramidal neurons in frontal and temporal cortex resulting from attenuation of FGFR1 signaling is associated with spontaneous hyperactivity in mice.
Topics: Adrenergic alpha-Agonists; Amphetamine; Animals; Cell Differentiation; Cell Division; Frontal Lobe; Glutamic Acid; Guanfacine; Humans; Hyperkinesis; Mice; Mice, Transgenic; Nervous System Malformations; Neural Inhibition; Pyramidal Cells; Receptor Protein-Tyrosine Kinases; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Adrenergic, alpha-2; Receptors, Fibroblast Growth Factor; Signal Transduction; Stereotypic Movement Disorder; Temporal Lobe | 2004 |
A case series on the heightened autonomic response due to guanfacine and amphetamine interaction.
Topics: Adrenergic alpha-Agonists; Amphetamine; Attention Deficit Disorder with Hyperactivity; Autonomic Nervous System Diseases; Blood Pressure; Central Nervous System Stimulants; Dopamine; Drug Interactions; Guanfacine; Humans | 2015 |
Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD.
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Costs; Drug Therapy, Combination; Female; Guanfacine; Health Care Costs; Humans; Lisdexamfetamine Dimesylate; Male; Markov Chains; Methylphenidate; Ontario; Quality-Adjusted Life Years | 2016 |